Cairo: The 12th edition of Pharmaconex, the leading event in the pharmaceutical industry, kicks off today and will run from September 1 to 3, 2025, at the Egypt International Exhibition Center in Cairo.

The current edition was held under the patronage of the Ministry of Planning and Economic Development, the Ministry of Investment and Foreign Trade, and the General Authority for Investment and Free Zones. It witnessed a large turnout on its first day, exceeding 5,000 specialists from around the world. This success reflects the exhibition's pivotal role in supporting the country's efforts to localize the pharmaceutical industry and strengthen supply chains.

Pharmaconex serves as a strategic platform that brings together various components of the pharmaceutical industry under one roof, from raw materials and biopharmaceuticals, to nutritional supplements, machinery and laboratory equipment, to packaging systems, laboratories, and contract manufacturing. This year, the exhibition's significance was highlighted by the wide participation of senior executives and industry leaders, such as Dr. Gamal El-Leithy, Chairman of the Chamber of Pharmaceutical and Cosmetic Industries; Ms. Zineb Marcel, Head of the Healthcare and Pharmaceutical Industries Sector at the Moroccan Agency for Investment Development and Exports ( AMDIE ); Dr. Abdallah El-Mesned, Chairman and Managing Director of Bana Medical Group; and Dr. Michael Gamal, Regional Director of the Arab-Brazilian Chamber of Commerce in Cairo. The event was also attended by the Ambassadors to Egypt: Mr. Suresh K. Reddy, Ambassador of India; Mr. Askar Genis, Ambassador of the Republic of Kazakhstan; and other prominent figures.

As part of its commitment to strengthening partnerships, this year's exhibition introduced new additions, including the launch of the "Supplements and Public Health Sector," in collaboration with the National Food Safety Authority, highlighting the growing role of the nutritional supplement market in Egypt and the region. Focus was not limited to this sector alone, but extended to include a rich agenda that included specialized conferences and sessions addressing pivotal issues such as sterile manufacturing, digital transformation, supply chain resilience, pharmaceutical engineering, and quality management.

The exhibition also provided participants with the opportunity to gain exposure to global expertise through the "Sterile Room Technologies" conference, held in partnership with European experts, in addition to distinguished events such as the "Women in Pharmaceuticals" forums, the "Pharma Awards" awards, and expert-led panel discussions on the future of the pharmaceutical industry.

Reflecting these efforts, the exhibition represents a strategic platform for enhancing cooperation between local and international companies in the pharmaceutical manufacturing field. It reflects the ongoing commitment of its organizers to developing the industry and providing innovative solutions that contribute to improving the quality of healthcare in Egypt and the region. The exhibition's importance is particularly significant in light of the Egyptian pharmaceutical market, which reached a value of approximately $3.1 billion in 2023 and is expected to reach $5.2 billion by 2030. This year's direct and indirect economic impact of the exhibition, which exceeded $38.8 million, represents a significant contribution to the national economy and supports the sector's competitiveness.

For his part, Dr. Gamal El-Leithy, Chairman of the Chamber of Pharmaceutical and Cosmetic Industries, stated : "This exhibition represents a strategic platform for enhancing cooperation between local and international companies in the field of pharmaceutical manufacturing. It reflects and reinforces the importance of the pharmaceutical sector in Egypt as a leader in Africa and the Middle East, with over 85 years of experience and highly qualified industrialists and scientists. We affirm our ongoing commitment to developing the industry and providing innovative solutions that contribute to the continued improvement of the healthcare landscape in Egypt and the region."

In the same context , Ms. Samar Awad, Director of Pharmaconex, expressed her pride in the exhibition's success, explaining: "Our journey began 12 years ago with a fundamental idea: to provide a platform that brings together pharmaceutical industry experts. Today, Pharmaconex has become a true driving force and a hub where major players in the region meet to shape the future of the sector. This year's edition was characterized by exceptional energy, with more than 350 exhibitors from 40 countries participating to build new partnerships and present innovative solutions. Participation was not limited to displaying only, but also included actual contributions to the development of emerging sectors such as nutritional supplements, where the commitment of major companies such as Eva Pharma and UGC Pharma to support the industry in all its aspects was highlighted. This makes Pharmaconex more than just an exhibition, but a platform that contributes to leading the pharmaceutical industry into the future."

She continued: "This edition embodies our vision of transforming Egypt into a leading regional pharmaceutical manufacturing hub in the Middle East and North Africa, at a time when the pharmaceutical market is witnessing tremendous growth. The North Africa market alone is expected to rise from $13 billion to $22 billion by 2025, while the entire Middle East and Africa market is expected to exceed $60 billion by 2028. Therefore, at Pharmaconex, we are working to enable the industry to capitalize on this regional momentum."

It's worth noting that PharmaConex is organized as part of the Informa Global Exhibition Series, alongside CPHI , the world's largest pharmaceutical industry exhibition, giving it a broader international dimension and credibility. The exhibition also received silver sponsorship from the Public Authority for Special Economic Zones and Free Zones in the Sultanate of Oman, a clear indication of regional investment interest in Egypt's growing position in the pharmaceutical industry.

-I finish-

#Corporate Data

Disclaimer for the content of press releases
The content of these press releases is provided by a third-party provider. We do not assume any responsibility for, nor do we have any control over, such content. This content is provided on an 'as is' and 'as available' basis and has not been edited in any way. Neither we nor our affiliates are responsible for the accuracy, endorsement, or completeness of the opinions, views, information, or materials contained in this content.
Press releases are provided for informational purposes only; the content does not imply legal, investment, or tax advice or any opinion regarding the suitability, value, or profitability of any particular portfolio or investment strategy. We, or our affiliates, will not be liable for any errors or inaccuracies in the content, or for any actions you take based on such content. You expressly agree and acknowledge that you bear full responsibility for the use of the information contained in these press releases.
To the extent permitted by applicable law, Refinitiv, its parent, subsidiaries, affiliates, and their respective shareholders, directors, officers, employees, agents, advertisers, content providers, and licensors (collectively, the “Refinitiv Parties”) will not be liable (either jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive, or exemplary damages; This includes, but is not limited to: lost profits, lost savings or revenue, whether caused by negligence, tort, contract or other liability theories, even if the Refinitiv Parties have been advised of the possibility of any such damages and losses or had actually anticipated their occurrence.